Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway

Rosiglitazone metformin adduct inhibits hepatocellular carcinoma proliferation via activation of AMPK/p21 pathway

Abstract Background Rosiglitazone metformin adduct (RZM) is a novel compound, synthesized from rosiglitazone (Ros) and metformin (Met) combined at a molar mass ratio of 1:1. Met and Ros are widely used together for treating type 2 diabetes to improve drug effectiveness and reduce adverse drug reacti...

Full description

Bibliographic Details
Main Authors: Yuyang Liu, Xiangnan Hu, Xuefeng Shan, Ke Chen, Hua Tang
Format: Article
Language:English
Published: BMC 2019-01-01
Series:Cancer Cell International
Subjects:
Rosiglitazone metformin adduct
Hepatocellular carcinoma
Proliferation
Metformin
AMPK/p21 pathway
Online Access:http://link.springer.com/article/10.1186/s12935-019-0732-2

Internet

http://link.springer.com/article/10.1186/s12935-019-0732-2

Similar Items